基于DECAF评分选择的慢阻肺急性加重家庭治疗:非劣效随机对照试验与经济评价
这项非劣效随机对照试验纳入118例DECAF 0或1分的低风险慢阻肺急性加重住院患者,比较家庭医院(HAH)与常规护理(UC)。HAH组90天平均费用低1016英镑,但单侧95%CI跨过非劣效界值150英镑;HAH组床位日更少,90%概率具成本效果,两组死亡与再入院相似,90%患者偏好HAH。
要点
- DECAF 0或1分低风险慢阻肺急性加重患者可考虑家庭医院治疗。
- HAH组90天费用平均低1016英镑,但未达预设非劣效界值。
- HAH组床位日显著少于UC组,90%概率具成本效果。
核心结论
- 基于低风险DECAF评分选择的家庭医院治疗安全、临床有效、具成本效果且多数患者偏好。
- 与早期模型相比,该选择方式更简单,约两倍患者符合条件。
- 引入DECAF与常规护理住院时间下降且无不良结局相关,支持用DECAF指导早期出院。
研究设计与样本
- 非劣效随机对照试验,纳入118例因低风险慢阻肺急性加重(DECAF 0或1分)住院的患者。
- 患者随机分配至家庭医院(HAH)或常规护理(UC)。
- 主要结局为90天健康与社会成本。
- 试验前瞻性注册号ISRCTN29082260。
主要发现
- HAH组90天平均费用低1016英镑,单侧95%CI为-2343至312英镑,跨过非劣效界值150英镑。
- 费用节省主要来自床位日减少:HAH组中位1天(IQR 1-7),UC组中位5天(IQR 2-12),P=0.001。
- UC组指数住院住院时间仅3天,比预期短2天。
- 基于质量调整生命年,HAH具成本效果的概率为90%。
- 两组90天内各1例死亡,再入院率相似,90%患者后续慢阻肺急性加重偏好HAH。
临床怎么用
- 对DECAF 0或1分的低风险慢阻肺急性加重住院患者,可考虑以家庭医院替代住院治疗。
- DECAF评分可用于指导早期出院决策,选择适合家庭治疗的患者。
局限性
- UC组指数住院住院时间仅3天,比预期短2天,可能影响费用比较。
- 主要成本结局的单侧95%CI跨过非劣效界值150英镑,非劣效性未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous models of Hospital at Home (HAH) for COPD exacerbation (ECOPD) were limited by the lack of a reliable prognostic score to guide patient selection. Approximately 50% of hospitalised patients have a low mortality risk by DECAF, thus are potentially suitable. METHODS: In a non-inferiority randomised controlled trial, 118 patients admitted with a low-risk ECOPD (DECAF 0 or 1) were recruited to HAH or usual care (UC). The primary outcome was health and social costs at 90 days. RESULTS: Mean 90-day costs were £1016 lower in HAH, but the one-sided 95% CI crossed the non-inferiority limit of £150 (CI -2343 to 312). Savings were primarily due to reduced hospital bed days: HAH=1 (IQR 1-7), UC=5 (IQR 2-12) (P=0.001). Length of stay during the index admission in UC was only 3 days, which was 2 days shorter than expected. Based on quality-adjusted life years, the probability of HAH being cost-effective was 90%. There was one death within 90 days in each arm, readmission rates were similar and 90% of patients preferred HAH for subsequent ECOPD. CONCLUSION: HAH selected by low-risk DECAF score was safe, clinically effective, cost-effective, and preferred by most patients. Compared with earlier models, selection is simpler and approximately twice as many patients are eligible. The introduction of DECAF was associated with a fall in UC length of stay without adverse outcome, supporting use of DECAF to direct early discharge. TRIAL REGISTRATION NUMBER: Registered prospectively ISRCTN29082260.
引用
- Echevarria C, Gray J, Hartley T, et al. Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation. Thorax. 2018. PMID: 29680821. doi:10.1136/thoraxjnl-2017-211197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。